牛熊異動 | 阿里健康破頂,牛證漲50%
三部門齊推“互聯網+醫療“ 京東健康(06618)、阿里健康(00241)均漲超4%破頂。看漲衍生品里康匯豐一七牛C(52917.HK)漲幅超50%。
【阿裏健康支持10倍槓桿日內交易】
近日,國家衛生健康委、國家醫療保障局、國家中醫藥管理局發佈《關於深入推進“互聯網+醫療健康”“五個一”服務行動的通知》(以下簡稱《通知》)。通知明確提出,全行業橫向、縱向要深化落實“五個一”服務。銀河證券認爲,“互聯網+”醫療的階段性痛點有望漸清除,行業有望迎來新的發展機遇。建議關注“互聯網+”醫療服務公司阿里健康(00241)、京東健康(06618)等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.